Long duration therapy (96 weeks) reduces relapse rate in chronic hepatitis C patients treated with Rebetron: A pilot study.

被引：0
|
作者：
Pimstone, NR [1 ]
Balasubramanian, S [1 ]
机构：
[1] Univ Calif Davis, Sch Med, Div Gastroenterol, Sacramento, CA 95817 USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1738
引用
收藏
页码：597A / 597A
页数：1
相关论文
共 50 条
  • [1] Ofloxacin plus interferon therapy in chronic hepatitis C. A pilot study.
    Castano, G
    Sookoian, S
    Flichman, D
    Viudez, P
    Frider, B
    HEPATOLOGY, 1997, 26 (04) : 1450 - 1450
  • [2] Efficacy of Rebetron (interferon and ribavirin) combination therapy in the treatment of patients with chronic hepatitis C not previously treated with interferon.
    Nelson, JB
    HEPATOLOGY, 2000, 32 (04) : 553A - 553A
  • [3] Impact of a dedicated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C
    Imperial, J
    Ahern, M
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A722
  • [4] Rebetron® therapy of chronic hepatitis C patients who were non-responsive to or relapsed on interferon monotherapy-predicting relapse.
    LaBrecque, DR
    Schmidt, WN
    Phillips, MJP
    Schrock, D
    Ippolito, L
    Juhl, R
    Voigt, MD
    Brashear, D
    Martin, AE
    Adler, EC
    Chene, BL
    Tamburro, CH
    GASTROENTEROLOGY, 2000, 118 (04) : A950 - A950
  • [5] Safety of interferon and ribavirin therapy in dialysis patient with chronic hepatitis C: Results of a pilot study.
    Tan, AC
    Brouwer, JT
    Van Leusen, R
    Kauffmann, RH
    Schalm, SW
    Vries, RA
    Vroom, B
    HEPATOLOGY, 1999, 30 (04) : 364A - 364A
  • [6] Intensive 4-weeks' mindfulness therapy in the treatment of chronic pain in patients with cancer: Pilot study.
    Kieszkowska-Grudny, Anna
    Pratnicka, Katarzyna
    Jarosz, Jerzy
    Jasinska, Dorota
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study
    Ohad Etzion
    Harel Dahari
    David Yardeni
    Assaf Issachar
    Anat Nevo-Shor
    Michal Cohen-Naftaly
    Yaffa Ashur
    Susan L. Uprichard
    Orly Sneh Arbib
    Daniela Munteanu
    Marius Braun
    Scott J. Cotler
    Naim Abufreha
    Ayelet Keren-Naus
    Yonat Shemer-Avni
    Orna Mor
    Jayanah Murad
    Victor Novack
    Amir Shlomai
    Scientific Reports, 10
  • [8] Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study
    Etzion, Ohad
    Dahari, Harel
    Yardeni, David
    Issachar, Assaf
    Nevo-Shor, Anat
    Cohen-Naftaly, Michal
    Ashur, Yaffa
    Uprichard, Susan L.
    Arbib, Orly Sneh
    Munteanu, Daniela
    Braun, Marius
    Cotler, Scott J.
    Abufreha, Naim
    Keren-Naus, Ayelet
    Shemer-Avni, Yonat
    Mor, Orna
    Murad, Jayanah
    Novack, Victor
    Shlomai, Amir
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [9] Pilot study of 12 weeks combination therapy with standard interferon and ribavirin in patients with chronic hepatitis C virus (HCV) infection
    Acharya, Subrat Kumar
    Chalamalasetty, Sreenivasa Baba
    Madan, Kaushal
    Batra, Y.
    Kumar, S.
    Kalra, N.
    Gupta, S. Datta
    Jha, J. K.
    Panda, S. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A467 - A467
  • [10] A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy
    Fong, TL
    Fried, MW
    Clarke-Platt, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (04) : 990 - 993
12345